1. Home
  2. SLP vs ENTA Comparison

SLP vs ENTA Comparison

Compare SLP & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Simulations Plus Inc.

SLP

Simulations Plus Inc.

HOLD

Current Price

$15.28

Market Cap

320.9M

Sector

Technology

ML Signal

HOLD

Logo Enanta Pharmaceuticals Inc.

ENTA

Enanta Pharmaceuticals Inc.

HOLD

Current Price

$14.08

Market Cap

374.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SLP
ENTA
Founded
1996
1995
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
320.9M
374.6M
IPO Year
1996
2012

Fundamental Metrics

Financial Performance
Metric
SLP
ENTA
Price
$15.28
$14.08
Analyst Decision
Buy
Strong Buy
Analyst Count
6
5
Target Price
$24.00
$20.40
AVG Volume (30 Days)
268.0K
171.2K
Earning Date
04-09-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
29.93
EPS
0.26
N/A
Revenue
$59,577,000.00
$102,814,000.00
Revenue This Year
$3.80
$7.76
Revenue Next Year
$5.90
N/A
P/E Ratio
$58.31
N/A
Revenue Growth
10.52
16.48
52 Week Low
$11.09
$5.74
52 Week High
$34.01
$17.15

Technical Indicators

Market Signals
Indicator
SLP
ENTA
Relative Strength Index (RSI) 58.69 49.53
Support Level $13.95 $13.19
Resistance Level $15.59 $15.48
Average True Range (ATR) 1.07 0.84
MACD -0.03 -0.11
Stochastic Oscillator 51.14 27.74

Price Performance

Historical Comparison
SLP
ENTA

About SLP Simulations Plus Inc.

Simulations Plus Inc is engaged in the software industry. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.

About ENTA Enanta Pharmaceuticals Inc.

Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.

Share on Social Networks: